Latest news with #digitalhealth
CBC
a day ago
- Health
- CBC
More patients using self-registration kiosks at P.E.I.'s 2 main hospitals, official says
Social Sharing Health P.E.I.'s self-registration kiosks are seeing an increase in use since they were put in last fall, a hospital manager says. The kiosks were installed in November 2024 at Prince County Hospital in Summerside and Queen Elizabeth Hospital in Charlottetown. "The idea behind it is to allow patients to self-register for scheduled appointments that they have for certain clinics," said Anne Douglas-Oakley, the manager of health records, admitting and telecommunications at PCH. "It's helping reduce wait times for registrations for people that would like to use it." It's most often used by people who come in for daily appointments — for example, to get a dressing changed on a wound or surgical site. In the first few months of the kiosks being in place, only a handful of people used them per day, Douglas-Oakley said. Now, about 15 or 20 people are using them each day, she said. Patients swipe health cards The installation of the kiosks is part of Health P.E.I.'s five-year digital health strategy. Patients can swipe their health card at the kiosk, where their appointment information shows up on a screen. Once patients confirm their personal information, their paperwork is sent to the clinic they are visiting for their appointment, Douglas-Oakley said. It's just another way for a patient to register. — Anne Douglas-Oakley While the option to self-register is available to patients, the option to speak face-to-face with a registration clerk remains available. Douglas-Oakley said the choice is comparable to the self-checkout option at the grocery store. "Some people prefer to use the self-checkout versus the cashier. Both are available, and it's just whatever they choose," she said. "Having the kiosks come in is not eliminating any jobs… It's just another way for a patient to register." Where the kiosks are used The kiosks are available only at the QEH and PCH ambulatory clinics, which register more than 300 outpatients a day for various services, Douglas-Oakley said. Laboratory and diagnostic imaging clinics still require face-to-face registration with a clerk. There are no plans to expand self-registration kiosks to emergency departments, Douglas-Oakley said.
Associated Press
a day ago
- Business
- Associated Press
h2o Therapeutics Receives European MDR Certification for Its Apple Watch-Based App for Parkinson's Disease
ANKARA, TR / ACCESS Newswire / May 30, 2025 / h2o Therapeutics announced that it has received European Union Medical Device Regulation (EU MDR) Class IIa certification for Parky, a mobile app designed to monitor and manage Parkinson's Disease (PD) symptoms via Apple Watch. This follows the 510(k) clearance previously granted by the U.S. Food and Drug Administration (FDA) in 2022, making Parky one of the few internationally regulated mobile medical apps specifically developed for Parkinson's. Parky utilizes Apple's Movement Disorder API to track motor symptoms such as tremors and dyskinesia in real time. The data is securely shared with healthcare professionals, allowing for continuous remote symptom tracking and personalized treatment adjustments. The underlying API was validated in a 343-participant study - 225 of whom were monitored for up to six months - referencing the gold-standard MDS-UPDRS clinical scale. The findings were published in Science Translational Medicine. With EU MDR Class IIa certification, Parky is now eligible for clinical use in over 30 countries that recognize the EU MDR regulatory framework, including all EU member states and multiple non-EU jurisdictions that adopt or align with these standards. 'Receiving EU MDR certification is another transformative milestone for us,' said Yagmur Selin Gulmus, founder of h2o Therapeutics. 'This recognition confirms our ability to meet the highest global standards in digital health. We're now actively seeking strategic partnerships to support Parky's global adoption and bring its benefits to Parkinson's communities worldwide.' Parkinson's Disease, affecting more than 10 million people globally, is the fastest-growing neurological disorder. Parky bridges the gap between episodic clinical assessments and real-world patient experience, enabling data-driven, individualized care through continuous passive monitoring. h2o Therapeutics is a digital health company developing clinically validated, wearable-integrated software solutions for neurological and chronic conditions. Based in Türkiye, the company combines rigorous regulatory pathways with consumer-first design to create prescription digital therapeutics (PDTs) that improve patient outcomes and support continuous, real-world care. Contact InformationBulutay Gunes Brand Manager SOURCE: h2o therapeutics press release
Yahoo
2 days ago
- Business
- Yahoo
Substance Abuse Treatment Market Forecast 2025-2030 with Tariff-Adjusted Growth Projections for the Short and Long Term
Features Profiles of Key Players Universal Health Services, Acadia Healthcare Company, American Addiction Centers, Advanced Recovery Systems, Hazelden Betty Ford Foundation and More Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Substance Abuse Treatment Market by Treatment Mode, Substance Type, Service Provider, End User, Payment Mode - Global Forecast to 2030" report has been added to Substance Abuse Treatment Market grew from USD 7.72 billion in 2024 to USD 8.52 billion in 2025. It is expected to continue growing at a CAGR of 10.09%, reaching USD 13.75 billion by substance abuse treatment arena is undergoing a fundamental transformation driven by the integration of digital health solutions and a shift toward holistic, patient-centered care. Telehealth platforms that once served as novelty offerings have rapidly become integral channels for therapy, counseling, and ongoing support, breaking down geographic barriers and democratizing access to specialized harm reduction strategies are gaining traction, fostering a care continuum that emphasizes stabilization and long-term recovery rather than acute intervention alone. This shift has prompted providers to develop hybrid models that blend intensive detoxification services with outpatient programs, ensuring continuity of care as patients transition across treatment the policy front, the gradual relaxation of prescribing restrictions for certain medications and the expansion of reimbursement pathways have incentivized the adoption of integrated treatment frameworks. Payors and policymakers are recognizing the cost-effectiveness of early intervention, spurring collaborations between public agencies and private stakeholders to scale preventive and post-acute support these developments underscore a strategic pivot from siloed interventions to interconnected ecosystems of care. Stakeholders equipped to harness these trends will lead the next wave of innovation, delivering more resilient, scalable, and personalized treatment the Ripple Effects of 2025 US Tariff ChangesThe implementation of new United States tariffs in 2025 has introduced a complex set of cost pressures across the substance abuse treatment supply chain. Equipment used in medical detoxification units, ranging from specialized monitoring devices to pharmaceutical imports, has experienced incremental price adjustments that ripple through operational budgets. Facilities reliant on imported components for advanced telehealth infrastructure have also felt the impact, resulting in strategic renegotiations with technology fiscal dynamics extend beyond hardware to the procurement of therapeutic supports, including digital cognitive behavioral therapy modules and virtual reality applications. As service providers absorb higher input costs, there is a discernible shift toward optimizing existing resources and exploring domestically produced alternatives. This realignment has stimulated partnerships with local manufacturers and software developers eager to offer compliant, cost-effective collaboration has similarly adapted, with cross-border research initiatives now factoring in tariff-induced variances when budgeting for multi-site clinical trials. Funding agencies and institutional stakeholders are recalibrating grant allocations to accommodate these emerging cost vectors without undermining the integrity of scientific the tariff framework introduces short-term constraints, it also catalyzes innovation in supply chain resilience and domestic capacity building. Organizations that proactively diversify sourcing strategies and engage in strategic alliances will be best positioned to mitigate financial headwinds and sustain high-quality treatment Regional Dynamics Shaping Treatment UptakeRegional landscapes display marked variation in treatment uptake, shaped by regulatory environments, funding priorities, and cultural perceptions. In the Americas, well-established reimbursement frameworks support a robust network of inpatient, outpatient, and telehealth services, with public-private collaborations driving continuous refinement of care standards. North America's advanced clinical infrastructure coexists with growing demand in Latin American urban centers, where nascent outpatient and homecare models are gaining Europe, Middle East, and Africa, policy heterogeneity yields pockets of excellence alongside underserved regions. Western Europe combines stringent quality controls with widespread insurance coverage, enabling diverse service providers to flourish. In contrast, parts of the Middle East and Africa are at earlier stages of infrastructure development, prompting international aid agencies and local stakeholders to co-invest in capacity building and Asia-Pacific region presents a mosaic of innovation and challenge. Developed markets leverage telehealth to bridge gaps in rural areas, while emerging economies confront stigma and limited funding. Governments are increasingly recognizing substance abuse as a public health priority, allocating resources to expand medical detoxification and outpatient programming. In metropolitan centers, digital platforms are accelerating patient engagement, and mobile health initiatives are redefining outreach regional insights emphasize the necessity of localized approaches that respect regulatory idiosyncrasies and cultural mores, enabling providers to tailor interventions for maximum on Leading Innovators Steering the Market ForwardA cohort of forward-looking organizations is setting new benchmarks in treatment delivery. Prominent hospital based centers are integrating advanced telemonitoring solutions to enhance continuity of care post-detoxification, while standalone rehabilitation facilities are forming strategic alliances with telehealth startups to extend behavioral counseling services. Specialty homecare providers are leveraging digital outreach programs that combine real-time data analytics with human coaching, resulting in improved adherence and relapse national chains have adopted cross-disciplinary care pathways, embedding psychiatric and social work expertise within inpatient and outpatient settings. This holistic approach underscores a broader industry trend toward converging medical and psychosocial interventions under unified operational frameworks. Concurrently, digital therapeutics companies are piloting app-based cognitive behavioral therapy protocols, with early results indicating measurable improvements in treatment extends to payer-provider collaborations, where value-based contracting models are incentivizing outcomes rather than service volume. These arrangements are compelling service providers to invest in outcome tracking and predictive analytics, thereby refining care strategies and optimizing resource allocation. Partnerships between rehabilitation centers and academic institutions are also fostering evidence-driven program enhancements, ensuring that clinical practices evolve in lockstep with research these company-level initiatives reflect an ecosystem in which technology, clinical excellence, and strategic alliances converge to elevate standards of care and patient Imperatives for Industry TrailblazersIndustry leaders must embrace a multipronged strategy that aligns clinical innovation with sustainable business models. First, expanding telehealth capabilities beyond basic video consultations to encompass remote monitoring, digital therapeutics, and virtual peer support communities will strengthen patient engagement and reduce attrition. Integrating these services with traditional care pathways can create seamless transitions across levels of program design is equally essential. Providers should leverage segmentation intelligence to develop targeted interventions for high-risk demographic groups and substance categories, ensuring that therapy modalities and counseling frameworks resonate with patient needs. Embedding family and community support mechanisms can further enhance recovery outcomes, particularly in outpatient and aftercare the operational front, diversifying procurement strategies and forging partnerships with domestic technology vendors can mitigate tariff-driven cost pressures. Aligning with payors to craft value-based reimbursement models will incentivize quality over volume, fostering long-term fiscal health and accountability. Collaboration with policymakers and advocacy groups can also accelerate regulatory reforms that expand access and destigmatize investing in robust data analytics infrastructure will empower decision-makers to track outcomes, identify emerging trends, and iterate on program design in near real-time. This data-driven approach will underpin continuous improvement, ensuring organizations remain adaptive in a rapidly evolving Segmentation & CoverageThis research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations: Treatment Mode Day Treatment Detoxification Medical Detox Non Medical Detox Inpatient Hospital Based Inpatient Residential Inpatient Outpatient Intensive Outpatient Program Standard Outpatient Program Telehealth Asynchronous Telehealth Synchronous Telehealth Substance Type Alcohol Cannabis Opioids Stimulants Service Provider Clinic Homecare Hospital Based Centre Standalone Rehab Center End User Adolescents Adults Geriatric Payment Mode Private Insurance Public Funding Self Pay This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions: Americas United States California Texas New York Florida Illinois Pennsylvania Ohio Canada Mexico Brazil Argentina Europe, Middle East & Africa United Kingdom Germany France Russia Italy Spain United Arab Emirates Saudi Arabia South Africa Denmark Netherlands Qatar Finland Sweden Nigeria Egypt Turkey Israel Norway Poland Switzerland Asia-Pacific China India Japan Australia South Korea Indonesia Thailand Philippines Malaysia Singapore Vietnam Taiwan This research report delves into recent significant developments and analyzes trends for each of the following companies: Universal Health Services, Inc. Acadia Healthcare Company, Inc. American Addiction Centers, Inc. Advanced Recovery Systems, LLC Hazelden Betty Ford Foundation CleanSlate Centers, LLC Recovery Centers of America, LLC Phoenix House Foundation Caron Treatment Centers, Inc. Odyssey House, Inc. Key Attributes Report Attribute Details No. of Pages 181 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $8.52 Billion Forecasted Market Value (USD) by 2030 $13.75 Billion Compound Annual Growth Rate 10% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
3 days ago
- Business
- Globe and Mail
$787 Billion Digital Healthcare Market Redfined: New Initiatives to Reduce Maternal Deaths and Hospital Nursing Costs from AI Powered Telehealth Company: VSee Health (Nasdaq: VSEE)
$VSEE Major Clients Include NASA, U.S. Department of Health and Human Services, McKesson, DaVita and the Entire Nation of Qatar AI-Powered Telehealth Provider with Modular, No-Code/Low-Code Platform. 1,000+ Clients Including NASA, U.S. Department of Health and Human Services, McKesson, DaVita, and the Entire Nation of Qatar. Enabling Seamless, Scalable and Secure Digital Health Solutions Across Hospitals, Governments and Enterprise Organizations. "Lego-like" Digital Health Building Blocks to Design a Flexible Telehealth System System Feature Seamless Electronic Health Record (EHR) Integration, Advanced Data Visualizations and Other Scalable Capabilities for Future Needs. Launched New AI-Powered Telehealth to Reduce Maternal Deaths in Remote Philippines. Telenursing Robotics Solution Targeting 3-5% Reduction in Hospital Nursing Costs. Strategic Hospital Pilots and Research Partnerships Position Company for Scalable Growth in $787B Digital Health Market. Shareholder Letter Issued on Company Accomplishments, Initiatives and Strong AI Powered Product Pipeline Setting a Path to Record Success in 2025 $444K County Government Contract, Expanding into Public Sector Healthcare. Partnership Agreement with LanguageLine to Boost Telehealth Adoption with Seamless, Scalable Multilingual Care. $560K Contract with Major Oncology Network. Top Kidney Care Provider to Add VSee Workflow to Oracle Cerner EHR. $2M Contract for Neurocritical Care Expansion at Leading Hospital with Autonomous Robotics and Industry-Disrupting Telenursing Model. Multiple Other Awards in 2025 including Multi-Year, $6M First Year, Government Contract to Deliver Rapid Configurable Telehealth. VSee Health (Nasdaq: VSEE) is a rapidly growing leader in AI-powered telehealth, redefining the $787 billion digital healthcare market with its modular, no-code/low-code platform. Trusted by 1,000+ clients, including NASA, the U.S. Department of Health and Human Services, McKesson, DaVita, and the entire nation of Qatar, VSEE accelerates telehealth adoption by enabling seamless, scalable and secure digital health solutions across hospitals, governments, and enterprise organizations. Field-tested with 1.5 million+ HIPAA-compliant video encounters per month, VSEE delivers turnkey solutions in critical care, teleradiology, and autonomous robotics, optimizing healthcare operations while increasing billable patient visits and provider efficiency. With a clear path to significant revenue growth and expanding margins, VSEE is positioned to become the foundational infrastructure of digital healthcare, transforming patient care, hospital workflows, and workforce utilization. VSEE has a strategic partnership with AbundaBox to launch AbundaLife™, a groundbreakinghealth record management innovative solution addresses one of the most pressing challenges in healthcare—fragmented medical records—by consolidating personal health data into one secure, comprehensive profile. AbundaLife, supported by VSEE Health's dynamic technology, empowers individuals to manage their health more effectively, enabling providers to deliver better-coordinated care and improving health outcomes. VSEE also has an agreement wih Ava Robotics, a developer of intelligent robots for the workplace, to develop telepresence solutions for the inpatient intensive care market, including the development of a VSEE -powered Ava robot that allows providers to extend their reach and provide personalized care remotely. Launch of AI-Powered Telehealth to Reduce Maternal Deaths in Remote Philippines On May 16th VSEE announced the launch of Project MAMA (Mom's AI for Maternity Aid), an innovative telehealth initiative to reduce high maternal mortality rates in rural, isolated Philippines communities of Zamboanga Sibugay. Working with maternal care physicians and specialists from Stanford University and Ateneo de Zamboanga University, VSEE technology bridges the gap in prenatal care access, enabling women in underserved areas to receive remote OB-GYN consultations via its comprehensive telehealth platform. The solution features AI chatbots responding in local languages, portable diagnostic devices (e.g. ultrasounds) and electronic health records (EHRs) — all operational within four days of deployment. The pilot program represents a VSEE broader vision of bringing accessible healthcare to underserved populations worldwide through adaptable, AI-enhanced telehealth solutions. Advanced Telenursing Robotics Solution Targeting 3-5% Reduction in Hospital Nursing Costs On April 16th VSEE announced completing development of its Telenursing Robotics solution—an AI-driven platform designed to automate routine nursing tasks and reduce labor costs. With nursing expenses representing approximately 60% of hospital operating budgets, this innovation directly targets one of the most pressing cost challenges in healthcare. Initial modeling suggests hospitals deploying the VSEE solution could reduce nursing-related expenses by 3–5%, while also enhancing patient throughput and experience. VSee Health Highlights AI-Powered Telehealth On April 2nd VSEE released an update highlighting how the Company is at the forefront, pioneering AI-driven telehealth solutions that are revolutionizing patient care. An AI-Powered, Modular Approach to Telehealth VSEE offers a modular, no-code/low-code telehealth platform that allows healthcare organizations to build customized solutions tailored to their specific needs. Dubbed as "Lego-like" digital health building blocks, this flexible system enables seamless Electronic Health Record (EHR) integration, advanced data visualizations, and scalable capabilities that prepare healthcare institutions for the future. Expanding Partnerships and Strategic Growth The VSEE growing client portfolio and strategic partnerships further cement its leadership in the digital health space: Government Expansion: A $444K county government contract to provide a white-label telehealth and data analytics platform for mental and behavioral health services, signaling VSEE expansion into public sector healthcare. Major Oncology Network: A $560K contract to implement a secure telehealth platform, showcasing VSEE ability to scale within specialty healthcare. Oracle Cerner EHR Integration: A partnership with a top kidney care provider to integrate VSEE workflow into Oracle Cerner EHR, boosting telehealth call completion rates by 88%. Robotic Innovations: A $2 million contract with a leading hospital for neurocritical care expansion, leveraging autonomous robotics and an industry-disrupting telenursing model. Government Multi-Year Contract: A multi-year contract valued at $6 million in its first year, allowing VSEE to deliver rapid-configurable telehealth solutions for a national healthcare program. Strategic Collaborations for Enhanced Telehealth Adoption Beyond direct contracts, VSEE is accelerating telehealth adoption through groundbreaking partnerships: AbundaBox Collaboration: Launching AbundaLife, a health record management platform that consolidates fragmented medical records into a secure, comprehensive profile. Ava Robotics Partnership: Developing telepresence robots for inpatient intensive care, enabling remote providers to offer real-time, personalized care. LanguageLine Solutions Integration: Facilitating one-touch interpreter access in over 240 languages, ensuring seamless multilingual healthcare services. Field-Tested, Scalable, and Secure Digital Health Infrastructure With over 1.5 million HIPAA-compliant video encounters per month, VSEE delivers turnkey telehealth solutions in critical care, teleradiology, and autonomous robotics. VSEE technology enhances hospital operations by increasing billable patient visits and optimizing provider efficiency. This ability to streamline operations while ensuring high-quality patient care positions VSEE as a foundational infrastructure provider in digital healthcare. Outlook Following Nasdaq Listing Since listing on Nasdaq in mid-2024, VSEE has expanded its market presence while navigating short-seller activity, a common occurrence among companies following SPAC mergers. The company reports a growing portfolio of contracts and continues to develop its AI-driven product offerings, with further updates expected in 2025. For more information on $VSEE visit: Disclosure listed on the CorporateAds website Media Contact Company Name: Vsee Health, Inc. Contact Person: Anne Chang Email: Send Email Phone: 626-513-1824 Address: One Gateway Center Suite 507 300 Washington St. City: Newton State: Massachusetts Country: United States Website:
Forbes
3 days ago
- Business
- Forbes
InnovationRx: Hinge May Herald A New Wave Of Digital Health IPOs
In this week's edition of InnovationRx, we look at how Hinge Health's successful IPO may be a trendsetter, Indian billionaire Kiran Mazumdar-Shaw's 'biosimilars' business, RFK's changes to Covid vaccine guidance and more. To get it in your inbox, subscribe here. Lex Annison, COO of Hinge Health, Gabriel Mecklenburg, executive chairman, Daniel Perez, CEO, Bianca Buck, head of investor relations, James Budge, CFO, and Jim Pursley, president, ring a ceremonial bell on the floor of the New York Stock Exchange during the company's IPO. © 2025 Bloomberg Finance LP Digital physical therapy company Hinge Health had its initial public offering last week, opening at $37.85. It's currently trading over 10% above that price, giving it a market cap of over $3.2 billion (though this is about half of its peak valuation in 2021). The company's product portfolio offers personalized care plans for patients with chronic conditions, as well as software that coordinates these plans with a patient's doctor. Virtual chronic care company Omada Health also filed to go public earlier this month, and that plus the success of Hinge's IPO may begin a new 'wave of digital health companies seeking a public listing following the COVID-19 pandemic,' Pitchbook analyst Aaron DeGagne wrote in a note last week. He identified several companies, including Spring Health, Zocdoc, Noom and Headspace, that 'will be closely watching Hinge Health's IPO outcome' to decide whether to start the process of going public this year. Kiran Mazumdar Guerin Blask for Forbes Kiran Mazumdar-Shaw's booming drug business started not in a laboratory but in a tin-roofed shed in Bengaluru, the city formerly known as Bangalore and the capital of the southern Indian state of Karnataka. Inside, the 25-year-old was using the knowledge she had learned studying beer brewing in Australia to ferment enzymes for customers like Ocean Spray cranberry juice. Originally she had wanted to be a brewer like her father, but it was 1978 and she couldn't find a job. No one wanted to hire a woman as a brewer. Distraught and disillusioned, Mazumdar-Shaw put her education to another use: making enzymes for industrial uses. In partnership with an Irish entrepreneur who owned a company called Biocon and was looking to expand to India, she set up shop inside that hot shed. 'I call myself an accidental entrepreneur,' she says. Today, Biocon, which is publicly traded in India, brings in $1.9 billion by selling dozens of generic drugs and 'biosimilar' medications. The company also does contract research for other companies through its publicly traded subsidiary Syngene. While Forbes Self-Made Women list includes only women from the United States, Mazumdar-Shaw would easily make the top 20 were she American. She is one of the world's wealthiest self-made female entrepreneurs, with a fortune that Forbes estimates to be $3.2 billion. The biggest part of her empire is a majority-owned private subsidiary called Biocon Biologics, which focuses on biosimilars and represents nearly 55% of the parent company's revenue. Akin to what generics are for chemically synthesized drugs, these cheaper alternatives mimic biologic drugs. As with generics, companies like Mazumdar-Shaw's are allowed to develop biosimilars after a brand-name drug's patents expire. 'These are very complex, expensive drugs, and therefore it's important that companies like ours focus on affordable access,' says Mazumdar-Shaw over tea served by a butler at her Manhattan apartment. Read more here. GSK and Spero Therapeutics announced that their phase 3 clinical trial of tebipenem HBr, an antibiotic geared towards treatment of UTIs, was stopped early after an interim analysis showed significant, positive results in the nearly 1,700 enrolled patients. An independent data monitoring committee recommended the halt, as the study met its primary endpoint of showing the drug was non-inferior to a combination of the antibiotics imipenem and cilastatin. The companies plan to submit the new antibiotic to the FDA for approval in the second half of this year. Plus: Gilgamesh Pharmaceuticals released positive topline results for its phase 2 clinical study of its drug candidate GM-2505 for the treatment of major depressive disorder, finding both rapid and durable decrease in symptoms for patients in the study. AI chatbots. Scribing tools. Insurance claims software. Electronic health records. Abhinav Shashank, cofounder and CEO of digital health startup Innovaccer, looks at all the new technology for healthcare providers and hospital systems and sees a big problem. 'Healthcare is the only place where technology came in and everything became more inefficient,' Shashank told Forbes. The problem is that large healthcare systems, which may have dozens of hospitals and thousands of physicians, have lots of data and a variety of tools to manage it, but no easy way to put them together. Last week, Innovaccer unveiled its solution to that problem: A new software platform called Gravity that's designed to be a one-stop shop for all those disparate tools and vast amounts of data. Read more here. Plus: Ambience Healthcare claims that a new study finds that its AI models reduce medical coding errors by over 25% compared to physicians. HHS Secretary Robert F. Kennedy, Jr. announced that the CDC would be dropping its recommendations for pregnant women and healthy children to receive Covid vaccines. This appears to be at odds with the FDA, which listed pregnancy as a reason for vaccination of people under 65 in its new guidance last week. Paul Offit, a vaccine expert at Children's Hospital of Pennsylvania, told Forbes that 'All this does is put children in harm's way and put pregnant women in harm's way.' RFK Jr. names familiar culprits for the 'sickest generation' in the first MAHA commission report on children's health. Some struggling biotechs are being dragged down by pricey leases, especially in industry hubs like Boston, San Francisco and San Diego. Eli Lilly is buying California-based SiteOne Therapeutics, which is developing a non-opioid pain drug, in a deal worth up to $1 billion. Neuralink, the Elon Musk-founded company developing brain-computer interfaces, has raised $600 million in a venture capital round valuing the company at $9 billion. Measles infections appear to be slowing down in Texas but they're ticking up in other states, including Iowa, which saw its first infection since 2019. Conservative groups are lobbying the Trump Administration for stricter guardrails around in vitro fertilization.
